Clinical trials: Metastatic Cancers
Advanced Cancer, Metastatic Cancer
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
- Trial name
- NCT04648202
- Testing
- FS120
- Where
- 9 sites in United States, Spain
- Volunteers
- 82 people
- Sponsor
- invoX Pharma Limited
Metastatic Breast Cancer
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
The purpose of the study is to determine if eniluracil/5-FU/leucovorin in metastatic breast cancer (MBC) may have efficacy and tolerability advantages over capecitabine monotherapy.
- Trial name
- NCT01231802
- Testing
- Eniluracil, 5-Fluorouracil, Leucovorin
- Where
- 16 sites in United States, Russia
- Volunteers
- 140 people
- Sponsor
- Adherex Technologies, Inc.
Metastatic Renal Cell Carcinoma
Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
The purpose of this study is to know about the quality of life of patients with metastatic renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who suffer from fatigue and hand-foot syndrome…
- Trial name
- TROYA (NCT02789137)
- Where
- 23 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Pfizer
Breast Cancer, Metastasis
Study of GPX-100 in the Treatment of Metastatic Breast Cancer
The purpose of this early Phase II multicenter trial is to determine the objective clinical response to GPX-100, an anthracycline similar to doxorubicin, in up to 40 patients with newly diagnosed metastatic breast cancer.
- Trial name
- NCT00123877
- Testing
- GPX-100 (13-deoxydoxorubicin)
- Where
- 3 sites in United States, Bulgaria
- Volunteers
- 40 people
- Sponsor
- Gem Pharmaceuticals
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
A Phase 2 Study of ABSK043 Combined With Osimertinib
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
- Trial name
- NCT07710612
- Testing
- ABSK043 in combination with Osimertinib
- Where
- 7 sites in China
- Volunteers
- 72 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Solid Tumor
Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors
This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors
- Trial name
- NCT06258330
- Testing
- AM003
- Where
- 5 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Aummune Ltd.
NSCLC Stage IIIB~IV
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
MS-20 was approved as the first oral cancer adjuvant new drug indicated for ameliorating fatigue and appetite loss associated with cancer chemotherapy via reshaping human gut ecosystem and restoring immunity.
- Trial name
- NCT04909034
- Testing
- MS-20
- Where
- 7 sites in Taiwan
- Volunteers
- 15 people
- Sponsor
- Microbio Co Ltd
Neoplasms, Breast
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.
- Trial name
- NCT00075270
- Testing
- Paclitaxel, GW572016 (Lapatinib)
- Where
- 177 sites in United States, Argentina and 23 more
- Volunteers
- 580 people
- Sponsor
- GlaxoSmithKline
Leukemia, Myelodysplastic Syndromes
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00020969
- Testing
- arsenic trioxide
- Where
- 8 sites in United States
- Sponsor
- CTI BioPharma
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
This is a phase 1b/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and pharmacokinetics /pharmacodynamics of AsiDNA in combination with olaparib in participants with recurrent…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
- Trial name
- NCT05700669
- Testing
- AsiDNA, Olaparib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Valerio Therapeutics
Melanoma, Non-small Cell Lung Cancer
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial.
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT04609566
- Testing
- brentuximab vedotin, pembrolizumab
- Where
- 90 sites in United States
- Volunteers
- 161 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Cancer of Unknown Primary Site
A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)
The purpose of this study is to evaluate the efficacy and safety of F520 combined with paclitaxel plus carboplatin as first-line treatment for cancer of unknown primary.This study consists of two parts, with a total planned…
- Trial name
- NCT07761429
- Testing
- F520 combined with chemotherapy
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
Advanced or Metastatic Breast Cancer
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.
- Trial name
- NCT04742153
- Testing
- MRG002
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Shanghai Miracogen Inc.
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
The purpose of this study is to test the feasibility and toxicity of administering intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM) malignancies.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00089245
- Testing
- Iodine I 131 MOAB 8H9
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Y-mAbs Therapeutics
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for…
- Trial name
- UPWARD (NCT01977651)
- Testing
- Enzalutamide
- Where
- 76 sites in United States, Argentina and 18 more
- Volunteers
- 424 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Locally Advanced or Metastatic NSCLC
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease…
- Trial name
- NCT07109531
- Testing
- ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one…
- Trial name
- DESTINY-LUNG02 (NCT04644237)
- Testing
- Trastuzumab deruxtecan
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 152 people
- Sponsor
- Daiichi Sankyo
Metastatic Colorectal Cancer
An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe
This is an observational study in which data from patients with metastatic colorectal cancer in three European countries who received STIVARGA® (regorafenib), are collected.
- Trial name
- RegoFlex EU (NCT05551039)
- Testing
- Retrospective patient chart review
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Bayer
Colorectal Cancer, Pancreatic Ductal Cancer
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
The primary objectives of Part 1 of this study are to: Assess the safety and tolerability of the combination of BGB-3245 and panitumumab in participants with advanced or metastatic colorectal cancer (CRC) with a known mutation…
- Conditions
- Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
- Trial name
- NCT06194877
- Testing
- BGB-3245, Panitumumab
- Where
- 5 sites in United States, Australia
- Volunteers
- 13 people
- Sponsor
- MapKure, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.